Sou Hu Cai Jing·2025-04-29 02:12Core Viewpoint - The healthcare sector is experiencing a strong upward trend, with significant growth in key companies and ETFs, particularly driven by the performance of WuXi AppTec and the overall positive market sentiment towards innovative pharmaceuticals [3][4]. Group 1: Market Performance - The Hang Seng Healthcare Index (HSHCI) rose by 1.54%, with notable increases in stocks such as WuXi AppTec (up 4.98%) and Kelun-Biotech (up 4.17%) [3]. - The Hang Seng Healthcare ETF (513060) increased by 1.26%, with a latest price of 0.48 yuan and a turnover rate of 2.11%, amounting to a transaction volume of 226 million yuan [3]. - Over the past month, the average daily trading volume of the Hang Seng Healthcare ETF reached 1.986 billion yuan, ranking first among comparable funds [3]. Group 2: Company Financials - WuXi AppTec reported a strong Q1 performance with revenue of 9.655 billion yuan, a year-on-year increase of 20.96%, and a net profit of 3.672 billion yuan, up 89.06% [3]. - This marks the first time since Q4 2022 that WuXi AppTec achieved double-digit growth in both revenue and net profit [3]. Group 3: ETF Performance and Metrics - The Hang Seng Healthcare ETF has a current scale of 10.648 billion yuan, ranking in the top third among comparable funds [4]. - The ETF's net value increased by 32.62% over the past year, with a maximum monthly return of 28.34% since inception [4]. - The ETF's Sharpe ratio for the past year is 1.73, indicating strong risk-adjusted returns [5][6]. Group 4: Valuation and Holdings - The Hang Seng Healthcare Index has a current price-to-earnings ratio (PE-TTM) of 24.1, which is below 95.29% of the historical data over the past year, indicating a low valuation [6]. - The top ten weighted stocks in the index account for 57.31% of the total, with significant contributions from companies like WuXi Biologics and BeiGene [6][8].